Allergy Therapeutics PLC Board Change (6841C)
19 June 2019 - 4:00PM
UK Regulatory
TIDMAGY
RNS Number : 6841C
Allergy Therapeutics PLC
19 June 2019
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Group")
Board Change
Appointment of Mary Tavener as Non-Executive Director
19 June 2019 Allergy Therapeutics plc (AIM: AGY), the fully
integrated commercial biotechnology company specialising in allergy
vaccines, announces that Mary Tavener will join the Board of
Allergy Therapeutics as a Non-Executive Director with immediate
effect. Mary will also join the Audit Committee of the Board and
will work closely with the current chair Stephen Smith in
anticipation of her succeeding Stephen as chair of the committee
after the Group publishes its final results for the year ended 30
June 2019 in September.
Mary has extensive experience in the healthcare sector, having
spent more than 19 years as Chief Financial Officer and Board
member of AIM listed Advanced Medical Solutions ("AMS"). At AMS,
Mary was responsible for strategy and risk management, finance,
operations, regulatory, and legal. During her tenure through to the
end of 2018, AMS delivered 15 consecutive years of growth, listed
on AIM, and successfully conducted several transformational M&A
deals. Mary is a Fellow of the Chartered Institute of Management
Accountants (FCMA) and a Fellow of the Association of Corporate
Treasurers (FCT). Prior to joining AMS, Mary was the Group
Financial Controller of BTP plc.
Commenting on the appointment, Peter Jensen, Chairman of Allergy
Therapeutics, said: "I am delighted to announce Mary's appointment
and welcome her to the Board. Mary has an excellent track record
and an impressive breadth of executive experience, and we look
forward to the invaluable and trusted perspective she will bring to
the Board."
Commenting on her appointment, Mary Tavener said: "Allergy
Therapeutics has an excellent growth story since its formation as a
small spinout from SmithKline Beecham in 1999. The business today
has a broad range of assets in clinical development, a global
presence across 23 markets, over 500 employees, and has achieved a
10% CAGR over the last 19 years as well as significant commercial
success. I look forward to working with the Board to further
develop Allergy's leading position in the allergen immunotherapy
sector."
Additional Information
In accordance with the AIM Rules, the following information
required to be disclosed in relation to Mary Tavener is set out
below. Other than this information, there is no further information
required to be disclosed under paragraph (g) of Schedule Two of the
AIM Rules.
Full name and age
Mary Geraldine Tavener, 57 years old
Current Directorships Past Directorships in the previous
five years
Cuddington & Sandiway Parish Playing Advanced Healthcare Systems Limited
Fields Association Limited
Advanced Medical Solutions (Uk)
Limited
Advanced Medical Solutions Group
plc
Advanced Medical Solutions Limited
Advanced Medical Solutions (Plymouth)
Limited
AMS Trustee Company Limited
Innovative Technologies Limited
Medlogic Global Holdings Limited
Advanced Medical Solutions (Europe)
Limited
Advanced Healthcare Systems Limited
Advanced Medical Solutions (UK)
Limited
Advanced Medical Solutions Group
plc
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Chief Financial Officer
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley, Emma Earl, Corporate Finance
Erik Anderson, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / David Daley / Nicholas Brown / Olivia
Manser
allergytherapeutics@consilium-comms.com
Stern Investor Relations, Inc.
+1 212 362 1200
Christina Tartaglia
christina@sternir.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial
biotechnology company focussed on the treatment and diagnosis of
allergic disorders, including aluminium free immunotherapy vaccines
that have the potential to cure disease. The Group sells
proprietary and third-party products from its subsidiaries in nine
major European countries and via distribution agreements in an
additional ten countries. Its broad pipeline of products in
clinical development include vaccines for grass, tree and house
dust mite, and peanut allergy vaccine in pre-clinical development.
Other adjuvant systems to boost performance of vaccines outside
allergy are also in development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with more than 11,000m(2) of
state-of-the-art MHRA-approved manufacturing facilities and
laboratories. The Group, which has achieved double digit compound
annual growth since formation, employs c.500 employees and is
listed on the London Stock Exchange (AIM:AGY). For more
information, please see www.allergytherapeutics.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOASFSEFAFUSEIM
(END) Dow Jones Newswires
June 19, 2019 02:00 ET (06:00 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2024 to May 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From May 2023 to May 2024
